#1 Clinical Trials Search in Europe

Riociguat

This article examines the use of Riociguat, a medication being studied in clinical trials for various conditions related to pulmonary hypertension and cardiovascular health. Riociguat works by stimulating an enzyme called soluble guanylate cyclase, which helps relax and widen blood vessels. Researchers are investigating its potential benefits for patients with pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and other related disorders. The trials aim to evaluate Riociguat’s safety, efficacy, and effects on symptoms, exercise capacity, and quality of life in these patient populations.

Table of Contents

What is Riociguat?

Riociguat, also known by its brand name Adempas, is a medication primarily used to treat certain types of pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs[1]. It was developed by Bayer Pharmaceuticals and has shown effectiveness in improving exercise capacity and reducing pulmonary artery pressure in patients with this condition[1].

How Riociguat Works

Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the body. It works by increasing the levels of a substance called cyclic guanosine monophosphate (cGMP) in the blood vessels of the lungs. This helps relax and widen these blood vessels, which in turn reduces blood pressure in the lungs and improves blood flow[1][2].

Unlike some other medications used for pulmonary hypertension, Riociguat can work even when levels of nitric oxide (a natural substance that helps relax blood vessels) are low. This makes it potentially more effective in certain situations[1].

Conditions Treated with Riociguat

Riociguat is primarily used to treat the following conditions:

  • Pulmonary Arterial Hypertension (PAH): A type of high blood pressure that affects the arteries in the lungs and the right side of the heart[2].
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A rare form of pulmonary hypertension caused by blood clots in the lungs that don’t dissolve over time[2][3].
  • High Altitude Pulmonary Edema (HAPE): A condition that can occur when ascending to high altitudes, causing fluid buildup in the lungs[1].

Research is also being conducted to explore its potential use in other conditions, such as:

  • Heart Failure with Preserved Ejection Fraction: A type of heart failure where the heart muscle contracts normally but doesn’t relax properly[5].
  • Scleroderma-associated Digital Ulcers: Painful sores on the fingers or toes that can occur in people with scleroderma, an autoimmune disease[6].
  • Sickle Cell Disease: An inherited blood disorder that affects the shape of red blood cells[7].

Dosage and Administration

Riociguat is typically taken as an oral tablet, usually three times a day. The dosage is often started low and gradually increased over several weeks, based on how well the patient tolerates the medication and their blood pressure readings[2][6].

Common dosages range from 0.5 mg to 2.5 mg three times daily, but the exact dose can vary depending on the specific condition being treated and individual patient factors[6].

Effectiveness of Riociguat

Clinical trials have shown that Riociguat can be effective in:

  • Improving exercise capacity, as measured by the 6-minute walk distance test[7][8].
  • Reducing pulmonary vascular resistance and mean pulmonary arterial pressure[2][8].
  • Improving cardiac output (the amount of blood pumped by the heart)[2].
  • Enhancing quality of life measures in patients with pulmonary hypertension[8].

Potential Side Effects

Like all medications, Riociguat can cause side effects. Some of the potential side effects observed in clinical trials include:

  • Headache
  • Dizziness
  • Digestive issues (such as nausea or diarrhea)
  • Low blood pressure

It’s important to note that not everyone experiences these side effects, and they may vary in severity. Always consult with your healthcare provider about potential side effects and how to manage them[7][8].

Ongoing Research

Researchers continue to study Riociguat to better understand its effects and explore its potential use in other conditions. Some areas of ongoing research include:

  • Its impact on right ventricular function in patients with pulmonary hypertension[2].
  • Its potential to improve exercise-induced pulmonary vascular dysfunction after treatments for CTEPH[3].
  • Its effects on digital ulcers in patients with scleroderma[6].
  • Its potential benefits in patients with sickle cell disease[7].
  • Its possible role in treating migraine headaches[9].

As research continues, our understanding of Riociguat and its potential uses may expand, potentially offering new treatment options for patients with various cardiovascular and pulmonary conditions.

Aspect Details
Drug Name Riociguat (also known as Adempas)
Mechanism of Action Stimulates soluble guanylate cyclase to relax and widen blood vessels
Main Conditions Studied Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension, Heart failure with preserved ejection fraction, Sickle cell disease, Systemic sclerosis with digital ulcers
Key Outcome Measures Pulmonary artery pressure, 6-minute walk distance, Quality of life scores, WHO functional class, Hemodynamic parameters
Dosing Typically 0.5 mg to 2.5 mg three times daily, often with dose titration
Safety Considerations Monitoring for hypotension, bleeding risks, and other side effects
Potential Benefits Improved exercise capacity, reduced pulmonary vascular resistance, better quality of life

FAQ

  • What is Riociguat and how does it work? Riociguat is a medication that stimulates an enzyme called soluble guanylate cyclase. This helps relax and widen blood vessels, particularly in the lungs. It works by enhancing the nitric oxide pathway, which is important for maintaining healthy blood flow.
  • What conditions is Riociguat being studied for in clinical trials? Riociguat is being investigated for several conditions, including pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, heart failure with preserved ejection fraction, sickle cell disease, and systemic sclerosis with digital ulcers.
  • What are some of the main outcomes being measured in Riociguat clinical trials? Key outcomes being assessed include changes in pulmonary artery pressure, exercise capacity (measured by 6-minute walk distance), quality of life scores, WHO functional class, and various hemodynamic parameters. Researchers are also monitoring safety and side effects.
  • How is Riociguat typically administered in these trials? Riociguat is usually given as an oral medication, with doses ranging from 0.5 mg to 2.5 mg taken three times daily. Many trials use a dose titration period to gradually increase the dose based on patient tolerability.
  • Are there any notable side effects or safety concerns with Riociguat? Common side effects may include headache, dizziness, and gastrointestinal issues. More serious concerns can include hypotension (low blood pressure) and bleeding risks. Patients are closely monitored during trials, especially during dose adjustments.

Ongoing Clinical Trials on Riociguat

  • Testing the safety of stopping riociguat in patients with chronic thromboembolic pulmonary hypertension after successful balloon pulmonary angioplasty treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effects of Riociguat for Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on the Effects of Riociguat in Patients with Early Pulmonary Vascular Disease

    Not recruiting

    1
    Investigated drugs:
    Austria France Germany Italy

  • Study on the Effects of Riociguat in Patients with Pulmonary Hypertension Due to Left Heart Failure

    Not recruiting

    1
    Investigated drugs:
    Czechia Germany Italy

  • Study on the Safety and Effects of Riociguat for Children Aged 6 to 17 with Pulmonary Arterial Hypertension

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

Glossary

  • Pulmonary hypertension: A condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure if left untreated.
  • Chronic thromboembolic pulmonary hypertension (CTEPH): A form of pulmonary hypertension caused by old blood clots in the lungs that have not dissolved over time.
  • Soluble guanylate cyclase (sGC): An enzyme that Riociguat stimulates to help relax and widen blood vessels, improving blood flow.
  • 6-minute walk distance (6MWD): A test used to measure exercise capacity by assessing how far a patient can walk in 6 minutes.
  • WHO functional class: A system used to classify the severity of symptoms in patients with pulmonary hypertension, ranging from Class I (minimal symptoms) to Class IV (severe limitations).
  • Hemodynamics: The study of blood flow in the circulatory system, including measurements of blood pressure and cardiac output.
  • Pulmonary vascular resistance (PVR): A measure of the resistance to blood flow in the pulmonary arteries.
  • N-terminal pro-brain natriuretic peptide (NT-proBNP): A biomarker used to assess heart failure and cardiovascular risk.
  • Digital ulcers: Painful sores on the fingers or toes, often associated with conditions like systemic sclerosis.
  • Echocardiography: An imaging technique that uses sound waves to create pictures of the heart, used to assess cardiac function and structure.

References

  1. https://clinicaltrials.gov/study/NCT02024386
  2. https://clinicaltrials.eu/trial/study-on-the-effects-of-riociguat-for-patients-with-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension/
  3. https://clinicaltrials.gov/study/NCT03409588
  4. https://clinicaltrials.gov/study/NCT01489488
  5. https://clinicaltrials.gov/study/NCT02744339
  6. https://clinicaltrials.gov/study/NCT02915835
  7. https://clinicaltrials.gov/study/NCT02633397
  8. https://clinicaltrials.eu/trial/study-on-the-effects-of-riociguat-in-patients-with-pulmonary-hypertension-due-to-left-heart-failure/
  9. https://clinicaltrials.gov/study/NCT05750446